nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—PTGS2—thyroid cancer	0.755	1	CbGaD
Triamcinolone—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00366	0.1	CbGpPWpGaD
Triamcinolone—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00275	0.0754	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00165	0.0452	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00164	0.0449	CbGpPWpGaD
Triamcinolone—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00149	0.041	CbGpPWpGaD
Triamcinolone—NR3C1—Nuclear Receptors—THRB—thyroid cancer	0.00139	0.038	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00138	0.0379	CbGpPWpGaD
Triamcinolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00129	0.0355	CbGpPWpGaD
Triamcinolone—Embolism venous—Epirubicin—thyroid cancer	0.00125	0.00598	CcSEcCtD
Triamcinolone—Hypernatraemia—Epirubicin—thyroid cancer	0.0012	0.00574	CcSEcCtD
Triamcinolone—Mood swings—Sorafenib—thyroid cancer	0.00117	0.00562	CcSEcCtD
Triamcinolone—Embolism venous—Doxorubicin—thyroid cancer	0.00116	0.00554	CcSEcCtD
Triamcinolone—Blindness—Epirubicin—thyroid cancer	0.00114	0.00545	CcSEcCtD
Triamcinolone—Arrhythmia—Vandetanib—thyroid cancer	0.00114	0.00543	CcSEcCtD
Triamcinolone—Hypernatraemia—Doxorubicin—thyroid cancer	0.00111	0.00531	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.0011	0.0301	CbGpPWpGaD
Triamcinolone—Dysgeusia—Vandetanib—thyroid cancer	0.00108	0.00519	CcSEcCtD
Triamcinolone—Skin hyperpigmentation—Epirubicin—thyroid cancer	0.00106	0.00508	CcSEcCtD
Triamcinolone—Blindness—Doxorubicin—thyroid cancer	0.00105	0.00505	CcSEcCtD
Triamcinolone—Pancreatitis—Sorafenib—thyroid cancer	0.00105	0.00503	CcSEcCtD
Triamcinolone—Optic neuritis—Epirubicin—thyroid cancer	0.00103	0.00491	CcSEcCtD
Triamcinolone—Folliculitis—Epirubicin—thyroid cancer	0.001	0.0048	CcSEcCtD
Triamcinolone—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000993	0.0272	CbGpPWpGaD
Triamcinolone—Embolism—Epirubicin—thyroid cancer	0.000983	0.0047	CcSEcCtD
Triamcinolone—Skin hyperpigmentation—Doxorubicin—thyroid cancer	0.000982	0.0047	CcSEcCtD
Triamcinolone—Loss of consciousness—Vandetanib—thyroid cancer	0.000973	0.00465	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000971	0.0266	CbGpPWpGaD
Triamcinolone—Cough—Vandetanib—thyroid cancer	0.000966	0.00462	CcSEcCtD
Triamcinolone—Convulsion—Vandetanib—thyroid cancer	0.000959	0.00459	CcSEcCtD
Triamcinolone—Hypertension—Vandetanib—thyroid cancer	0.000956	0.00457	CcSEcCtD
Triamcinolone—Optic neuritis—Doxorubicin—thyroid cancer	0.00095	0.00454	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Sorafenib—thyroid cancer	0.000942	0.00451	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000937	0.00448	CcSEcCtD
Triamcinolone—Myocardial infarction—Sorafenib—thyroid cancer	0.000937	0.00448	CcSEcCtD
Triamcinolone—Folliculitis—Doxorubicin—thyroid cancer	0.000929	0.00445	CcSEcCtD
Triamcinolone—Dry mouth—Vandetanib—thyroid cancer	0.000922	0.00441	CcSEcCtD
Triamcinolone—NR3C1—Endoderm Differentiation—NKX2-1—thyroid cancer	0.000913	0.025	CbGpPWpGaD
Triamcinolone—NR3C1—Transcription factor regulation in adipogenesis—RXRA—thyroid cancer	0.000913	0.025	CbGpPWpGaD
Triamcinolone—Embolism—Doxorubicin—thyroid cancer	0.00091	0.00435	CcSEcCtD
Triamcinolone—Oedema—Vandetanib—thyroid cancer	0.000903	0.00432	CcSEcCtD
Triamcinolone—Epistaxis—Sorafenib—thyroid cancer	0.000901	0.00431	CcSEcCtD
Triamcinolone—Infection—Vandetanib—thyroid cancer	0.000897	0.00429	CcSEcCtD
Triamcinolone—Hepatomegaly—Epirubicin—thyroid cancer	0.000892	0.00427	CcSEcCtD
Triamcinolone—Blister—Epirubicin—thyroid cancer	0.000876	0.00419	CcSEcCtD
Triamcinolone—Haemoglobin—Sorafenib—thyroid cancer	0.000862	0.00412	CcSEcCtD
Triamcinolone—Haemorrhage—Sorafenib—thyroid cancer	0.000858	0.0041	CcSEcCtD
Triamcinolone—Dermatitis atopic—Epirubicin—thyroid cancer	0.000853	0.00408	CcSEcCtD
Triamcinolone—Neuritis—Epirubicin—thyroid cancer	0.000845	0.00405	CcSEcCtD
Triamcinolone—Hepatomegaly—Doxorubicin—thyroid cancer	0.000825	0.00395	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000823	0.00394	CcSEcCtD
Triamcinolone—Insomnia—Vandetanib—thyroid cancer	0.000817	0.00391	CcSEcCtD
Triamcinolone—Paraesthesia—Vandetanib—thyroid cancer	0.000811	0.00388	CcSEcCtD
Triamcinolone—Blister—Doxorubicin—thyroid cancer	0.00081	0.00388	CcSEcCtD
Triamcinolone—Dyspnoea—Vandetanib—thyroid cancer	0.000805	0.00385	CcSEcCtD
Triamcinolone—Abscess—Epirubicin—thyroid cancer	0.000798	0.00382	CcSEcCtD
Triamcinolone—Dyspepsia—Vandetanib—thyroid cancer	0.000795	0.0038	CcSEcCtD
Triamcinolone—Dermatitis atopic—Doxorubicin—thyroid cancer	0.000789	0.00378	CcSEcCtD
Triamcinolone—Neuritis—Doxorubicin—thyroid cancer	0.000782	0.00374	CcSEcCtD
Triamcinolone—Stinging—Epirubicin—thyroid cancer	0.000779	0.00373	CcSEcCtD
Triamcinolone—Glycosuria—Epirubicin—thyroid cancer	0.000779	0.00373	CcSEcCtD
Triamcinolone—Fatigue—Vandetanib—thyroid cancer	0.000779	0.00373	CcSEcCtD
Triamcinolone—Pain—Vandetanib—thyroid cancer	0.000773	0.0037	CcSEcCtD
Triamcinolone—Petechiae—Epirubicin—thyroid cancer	0.000767	0.00367	CcSEcCtD
Triamcinolone—Arrhythmia—Sorafenib—thyroid cancer	0.000766	0.00367	CcSEcCtD
Triamcinolone—Erythema—Sorafenib—thyroid cancer	0.000747	0.00357	CcSEcCtD
Triamcinolone—Abscess—Doxorubicin—thyroid cancer	0.000738	0.00353	CcSEcCtD
Triamcinolone—Dysgeusia—Sorafenib—thyroid cancer	0.000731	0.0035	CcSEcCtD
Triamcinolone—Glycosuria—Doxorubicin—thyroid cancer	0.000721	0.00345	CcSEcCtD
Triamcinolone—Stinging—Doxorubicin—thyroid cancer	0.000721	0.00345	CcSEcCtD
Triamcinolone—Body temperature increased—Vandetanib—thyroid cancer	0.000714	0.00342	CcSEcCtD
Triamcinolone—Petechiae—Doxorubicin—thyroid cancer	0.00071	0.0034	CcSEcCtD
Triamcinolone—Arthropathy—Epirubicin—thyroid cancer	0.000694	0.00332	CcSEcCtD
Triamcinolone—Cough increased—Epirubicin—thyroid cancer	0.00069	0.0033	CcSEcCtD
Triamcinolone—Angioedema—Sorafenib—thyroid cancer	0.000682	0.00326	CcSEcCtD
Triamcinolone—Syncope—Sorafenib—thyroid cancer	0.00067	0.0032	CcSEcCtD
Triamcinolone—Ulcer—Epirubicin—thyroid cancer	0.000667	0.00319	CcSEcCtD
Triamcinolone—Loss of consciousness—Sorafenib—thyroid cancer	0.000656	0.00314	CcSEcCtD
Triamcinolone—Cough—Sorafenib—thyroid cancer	0.000652	0.00312	CcSEcCtD
Triamcinolone—Asthenia—Vandetanib—thyroid cancer	0.000648	0.0031	CcSEcCtD
Triamcinolone—Hypertension—Sorafenib—thyroid cancer	0.000645	0.00308	CcSEcCtD
Triamcinolone—Arthropathy—Doxorubicin—thyroid cancer	0.000642	0.00307	CcSEcCtD
Triamcinolone—Pruritus—Vandetanib—thyroid cancer	0.000639	0.00306	CcSEcCtD
Triamcinolone—Cough increased—Doxorubicin—thyroid cancer	0.000638	0.00305	CcSEcCtD
Triamcinolone—Myalgia—Sorafenib—thyroid cancer	0.000636	0.00304	CcSEcCtD
Triamcinolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—thyroid cancer	0.000631	0.0173	CbGpPWpGaD
Triamcinolone—Hiccups—Epirubicin—thyroid cancer	0.000631	0.00302	CcSEcCtD
Triamcinolone—Dermatitis contact—Epirubicin—thyroid cancer	0.000624	0.00298	CcSEcCtD
Triamcinolone—Dry mouth—Sorafenib—thyroid cancer	0.000622	0.00297	CcSEcCtD
Triamcinolone—Ulcer—Doxorubicin—thyroid cancer	0.000617	0.00295	CcSEcCtD
Triamcinolone—Anaphylactic shock—Sorafenib—thyroid cancer	0.000609	0.00292	CcSEcCtD
Triamcinolone—Infection—Sorafenib—thyroid cancer	0.000605	0.0029	CcSEcCtD
Triamcinolone—Skin exfoliation—Epirubicin—thyroid cancer	0.000603	0.00288	CcSEcCtD
Triamcinolone—Candida infection—Epirubicin—thyroid cancer	0.000603	0.00288	CcSEcCtD
Triamcinolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—RXRA—thyroid cancer	0.000602	0.0165	CbGpPWpGaD
Triamcinolone—Shock—Sorafenib—thyroid cancer	0.0006	0.00287	CcSEcCtD
Triamcinolone—Fluid retention—Epirubicin—thyroid cancer	0.000599	0.00287	CcSEcCtD
Triamcinolone—Dizziness—Vandetanib—thyroid cancer	0.000597	0.00286	CcSEcCtD
Triamcinolone—Neuropathy—Epirubicin—thyroid cancer	0.000593	0.00284	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptors—RXRA—thyroid cancer	0.00059	0.0162	CbGpPWpGaD
Triamcinolone—Hiccups—Doxorubicin—thyroid cancer	0.000584	0.00279	CcSEcCtD
Triamcinolone—Dermatitis contact—Doxorubicin—thyroid cancer	0.000577	0.00276	CcSEcCtD
Triamcinolone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—thyroid cancer	0.000576	0.0158	CbGpPWpGaD
Triamcinolone—Vomiting—Vandetanib—thyroid cancer	0.000574	0.00275	CcSEcCtD
Triamcinolone—Ecchymosis—Epirubicin—thyroid cancer	0.000571	0.00273	CcSEcCtD
Triamcinolone—Rash—Vandetanib—thyroid cancer	0.00057	0.00273	CcSEcCtD
Triamcinolone—Dermatitis—Vandetanib—thyroid cancer	0.000569	0.00272	CcSEcCtD
Triamcinolone—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000568	0.0156	CbGpPWpGaD
Triamcinolone—Headache—Vandetanib—thyroid cancer	0.000566	0.00271	CcSEcCtD
Triamcinolone—Pulmonary oedema—Epirubicin—thyroid cancer	0.000562	0.00269	CcSEcCtD
Triamcinolone—Candida infection—Doxorubicin—thyroid cancer	0.000558	0.00267	CcSEcCtD
Triamcinolone—Skin exfoliation—Doxorubicin—thyroid cancer	0.000558	0.00267	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000555	0.00266	CcSEcCtD
Triamcinolone—Fluid retention—Doxorubicin—thyroid cancer	0.000554	0.00265	CcSEcCtD
Triamcinolone—Neuropathy—Doxorubicin—thyroid cancer	0.000548	0.00262	CcSEcCtD
Triamcinolone—Dyspnoea—Sorafenib—thyroid cancer	0.000543	0.0026	CcSEcCtD
Triamcinolone—Nausea—Vandetanib—thyroid cancer	0.000537	0.00257	CcSEcCtD
Triamcinolone—Dyspepsia—Sorafenib—thyroid cancer	0.000536	0.00257	CcSEcCtD
Triamcinolone—Thrombophlebitis—Epirubicin—thyroid cancer	0.000529	0.00253	CcSEcCtD
Triamcinolone—Ecchymosis—Doxorubicin—thyroid cancer	0.000528	0.00253	CcSEcCtD
Triamcinolone—Diabetes mellitus—Epirubicin—thyroid cancer	0.000527	0.00252	CcSEcCtD
Triamcinolone—Fatigue—Sorafenib—thyroid cancer	0.000525	0.00251	CcSEcCtD
Triamcinolone—Pain—Sorafenib—thyroid cancer	0.000521	0.00249	CcSEcCtD
Triamcinolone—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00052	0.00249	CcSEcCtD
Triamcinolone—Vascular purpura—Epirubicin—thyroid cancer	0.000512	0.00245	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000505	0.00242	CcSEcCtD
Triamcinolone—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00049	0.00234	CcSEcCtD
Triamcinolone—Increased appetite—Epirubicin—thyroid cancer	0.000488	0.00233	CcSEcCtD
Triamcinolone—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000487	0.00233	CcSEcCtD
Triamcinolone—Urticaria—Sorafenib—thyroid cancer	0.000484	0.00232	CcSEcCtD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000482	0.0132	CbGpPWpGaD
Triamcinolone—Body temperature increased—Sorafenib—thyroid cancer	0.000482	0.0023	CcSEcCtD
Triamcinolone—Dermatitis bullous—Epirubicin—thyroid cancer	0.000479	0.00229	CcSEcCtD
Triamcinolone—Purpura—Epirubicin—thyroid cancer	0.000475	0.00227	CcSEcCtD
Triamcinolone—Vascular purpura—Doxorubicin—thyroid cancer	0.000474	0.00227	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000473	0.00227	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000468	0.00224	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.000466	0.0128	CbGpPWpGaD
Triamcinolone—Osteoarthritis—Epirubicin—thyroid cancer	0.000458	0.00219	CcSEcCtD
Triamcinolone—NR3C1—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.000452	0.0124	CbGpPWpGaD
Triamcinolone—Increased appetite—Doxorubicin—thyroid cancer	0.000451	0.00216	CcSEcCtD
Triamcinolone—Affect lability—Epirubicin—thyroid cancer	0.000451	0.00216	CcSEcCtD
Triamcinolone—Hypersensitivity—Sorafenib—thyroid cancer	0.000449	0.00215	CcSEcCtD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000448	0.0123	CbGpPWpGaD
Triamcinolone—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000444	0.00212	CcSEcCtD
Triamcinolone—Purpura—Doxorubicin—thyroid cancer	0.00044	0.0021	CcSEcCtD
Triamcinolone—NR3C1—Circadian Clock—RXRA—thyroid cancer	0.000439	0.012	CbGpPWpGaD
Triamcinolone—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000438	0.0021	CcSEcCtD
Triamcinolone—Asthenia—Sorafenib—thyroid cancer	0.000437	0.00209	CcSEcCtD
Triamcinolone—Cardiac arrest—Epirubicin—thyroid cancer	0.000436	0.00208	CcSEcCtD
Triamcinolone—Mood swings—Epirubicin—thyroid cancer	0.000434	0.00208	CcSEcCtD
Triamcinolone—Pruritus—Sorafenib—thyroid cancer	0.000431	0.00206	CcSEcCtD
Triamcinolone—Osteoarthritis—Doxorubicin—thyroid cancer	0.000424	0.00203	CcSEcCtD
Triamcinolone—Affect lability—Doxorubicin—thyroid cancer	0.000417	0.002	CcSEcCtD
Triamcinolone—Muscular weakness—Epirubicin—thyroid cancer	0.000404	0.00193	CcSEcCtD
Triamcinolone—Cardiac arrest—Doxorubicin—thyroid cancer	0.000403	0.00193	CcSEcCtD
Triamcinolone—Dizziness—Sorafenib—thyroid cancer	0.000403	0.00193	CcSEcCtD
Triamcinolone—Mood swings—Doxorubicin—thyroid cancer	0.000402	0.00192	CcSEcCtD
Triamcinolone—Abdominal distension—Epirubicin—thyroid cancer	0.000399	0.00191	CcSEcCtD
Triamcinolone—Asthma—Epirubicin—thyroid cancer	0.000396	0.00189	CcSEcCtD
Triamcinolone—Influenza—Epirubicin—thyroid cancer	0.000396	0.00189	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—CDK1—thyroid cancer	0.00039	0.0107	CbGpPWpGaD
Triamcinolone—Pancreatitis—Epirubicin—thyroid cancer	0.000388	0.00186	CcSEcCtD
Triamcinolone—Vomiting—Sorafenib—thyroid cancer	0.000387	0.00185	CcSEcCtD
Triamcinolone—Rash—Sorafenib—thyroid cancer	0.000384	0.00184	CcSEcCtD
Triamcinolone—Dermatitis—Sorafenib—thyroid cancer	0.000384	0.00184	CcSEcCtD
Triamcinolone—Headache—Sorafenib—thyroid cancer	0.000382	0.00183	CcSEcCtD
Triamcinolone—Bronchitis—Epirubicin—thyroid cancer	0.000381	0.00182	CcSEcCtD
Triamcinolone—Muscular weakness—Doxorubicin—thyroid cancer	0.000374	0.00179	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptors—PPARG—thyroid cancer	0.000372	0.0102	CbGpPWpGaD
Triamcinolone—Abdominal distension—Doxorubicin—thyroid cancer	0.000369	0.00176	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000368	0.00176	CcSEcCtD
Triamcinolone—Asthma—Doxorubicin—thyroid cancer	0.000366	0.00175	CcSEcCtD
Triamcinolone—Influenza—Doxorubicin—thyroid cancer	0.000366	0.00175	CcSEcCtD
Triamcinolone—Nausea—Sorafenib—thyroid cancer	0.000362	0.00173	CcSEcCtD
Triamcinolone—Weight increased—Epirubicin—thyroid cancer	0.00036	0.00172	CcSEcCtD
Triamcinolone—Pancreatitis—Doxorubicin—thyroid cancer	0.000359	0.00172	CcSEcCtD
Triamcinolone—Bronchitis—Doxorubicin—thyroid cancer	0.000352	0.00169	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000346	0.00166	CcSEcCtD
Triamcinolone—Conjunctivitis—Epirubicin—thyroid cancer	0.000343	0.00164	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000341	0.00163	CcSEcCtD
Triamcinolone—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00034	0.00931	CbGpPWpGaD
Triamcinolone—Weight increased—Doxorubicin—thyroid cancer	0.000333	0.0016	CcSEcCtD
Triamcinolone—Epistaxis—Epirubicin—thyroid cancer	0.000333	0.00159	CcSEcCtD
Triamcinolone—NR3C1—Circadian Clock—HIF1A—thyroid cancer	0.000326	0.00893	CbGpPWpGaD
Triamcinolone—Bradycardia—Epirubicin—thyroid cancer	0.000323	0.00154	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00032	0.00153	CcSEcCtD
Triamcinolone—Haemoglobin—Epirubicin—thyroid cancer	0.000319	0.00152	CcSEcCtD
Triamcinolone—Rhinitis—Epirubicin—thyroid cancer	0.000318	0.00152	CcSEcCtD
Triamcinolone—Conjunctivitis—Doxorubicin—thyroid cancer	0.000318	0.00152	CcSEcCtD
Triamcinolone—Haemorrhage—Epirubicin—thyroid cancer	0.000317	0.00152	CcSEcCtD
Triamcinolone—Pharyngitis—Epirubicin—thyroid cancer	0.000315	0.00151	CcSEcCtD
Triamcinolone—Epistaxis—Doxorubicin—thyroid cancer	0.000308	0.00147	CcSEcCtD
Triamcinolone—Bradycardia—Doxorubicin—thyroid cancer	0.000299	0.00143	CcSEcCtD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000298	0.00817	CbGpPWpGaD
Triamcinolone—Haemoglobin—Doxorubicin—thyroid cancer	0.000295	0.00141	CcSEcCtD
Triamcinolone—NR3C1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000294	0.00806	CbGpPWpGaD
Triamcinolone—Rhinitis—Doxorubicin—thyroid cancer	0.000294	0.00141	CcSEcCtD
Triamcinolone—Haemorrhage—Doxorubicin—thyroid cancer	0.000293	0.0014	CcSEcCtD
Triamcinolone—Pharyngitis—Doxorubicin—thyroid cancer	0.000291	0.00139	CcSEcCtD
Triamcinolone—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000285	0.0078	CbGpPWpGaD
Triamcinolone—Arrhythmia—Epirubicin—thyroid cancer	0.000283	0.00135	CcSEcCtD
Triamcinolone—Erythema—Epirubicin—thyroid cancer	0.000276	0.00132	CcSEcCtD
Triamcinolone—Dysgeusia—Epirubicin—thyroid cancer	0.00027	0.00129	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.000269	0.00736	CbGpPWpGaD
Triamcinolone—Back pain—Epirubicin—thyroid cancer	0.000267	0.00128	CcSEcCtD
Triamcinolone—NR3C1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000262	0.00718	CbGpPWpGaD
Triamcinolone—Arrhythmia—Doxorubicin—thyroid cancer	0.000262	0.00125	CcSEcCtD
Triamcinolone—Ill-defined disorder—Epirubicin—thyroid cancer	0.000256	0.00122	CcSEcCtD
Triamcinolone—Erythema—Doxorubicin—thyroid cancer	0.000255	0.00122	CcSEcCtD
Triamcinolone—Dysgeusia—Doxorubicin—thyroid cancer	0.00025	0.0012	CcSEcCtD
Triamcinolone—Malaise—Epirubicin—thyroid cancer	0.000249	0.00119	CcSEcCtD
Triamcinolone—Vertigo—Epirubicin—thyroid cancer	0.000248	0.00119	CcSEcCtD
Triamcinolone—Syncope—Epirubicin—thyroid cancer	0.000247	0.00118	CcSEcCtD
Triamcinolone—Back pain—Doxorubicin—thyroid cancer	0.000247	0.00118	CcSEcCtD
Triamcinolone—Loss of consciousness—Epirubicin—thyroid cancer	0.000243	0.00116	CcSEcCtD
Triamcinolone—Cough—Epirubicin—thyroid cancer	0.000241	0.00115	CcSEcCtD
Triamcinolone—Convulsion—Epirubicin—thyroid cancer	0.000239	0.00114	CcSEcCtD
Triamcinolone—Hypertension—Epirubicin—thyroid cancer	0.000238	0.00114	CcSEcCtD
Triamcinolone—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000237	0.00113	CcSEcCtD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000236	0.00646	CbGpPWpGaD
Triamcinolone—Myalgia—Epirubicin—thyroid cancer	0.000235	0.00112	CcSEcCtD
Triamcinolone—Discomfort—Epirubicin—thyroid cancer	0.000232	0.00111	CcSEcCtD
Triamcinolone—Malaise—Doxorubicin—thyroid cancer	0.00023	0.0011	CcSEcCtD
Triamcinolone—Dry mouth—Epirubicin—thyroid cancer	0.00023	0.0011	CcSEcCtD
Triamcinolone—Vertigo—Doxorubicin—thyroid cancer	0.000229	0.0011	CcSEcCtD
Triamcinolone—Syncope—Doxorubicin—thyroid cancer	0.000229	0.0011	CcSEcCtD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000227	0.00621	CbGpPWpGaD
Triamcinolone—Anaphylactic shock—Epirubicin—thyroid cancer	0.000225	0.00108	CcSEcCtD
Triamcinolone—Oedema—Epirubicin—thyroid cancer	0.000225	0.00108	CcSEcCtD
Triamcinolone—Loss of consciousness—Doxorubicin—thyroid cancer	0.000224	0.00107	CcSEcCtD
Triamcinolone—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000224	0.00614	CbGpPWpGaD
Triamcinolone—Infection—Epirubicin—thyroid cancer	0.000224	0.00107	CcSEcCtD
Triamcinolone—Cough—Doxorubicin—thyroid cancer	0.000223	0.00107	CcSEcCtD
Triamcinolone—Shock—Epirubicin—thyroid cancer	0.000222	0.00106	CcSEcCtD
Triamcinolone—Convulsion—Doxorubicin—thyroid cancer	0.000221	0.00106	CcSEcCtD
Triamcinolone—Hypertension—Doxorubicin—thyroid cancer	0.00022	0.00105	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—RXRA—thyroid cancer	0.00022	0.00604	CbGpPWpGaD
Triamcinolone—Tachycardia—Epirubicin—thyroid cancer	0.00022	0.00105	CcSEcCtD
Triamcinolone—Hyperhidrosis—Epirubicin—thyroid cancer	0.000218	0.00104	CcSEcCtD
Triamcinolone—Myalgia—Doxorubicin—thyroid cancer	0.000217	0.00104	CcSEcCtD
Triamcinolone—Discomfort—Doxorubicin—thyroid cancer	0.000215	0.00103	CcSEcCtD
Triamcinolone—Dry mouth—Doxorubicin—thyroid cancer	0.000213	0.00102	CcSEcCtD
Triamcinolone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000208	0.000997	CcSEcCtD
Triamcinolone—Oedema—Doxorubicin—thyroid cancer	0.000208	0.000997	CcSEcCtD
Triamcinolone—Infection—Doxorubicin—thyroid cancer	0.000207	0.00099	CcSEcCtD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000206	0.00565	CbGpPWpGaD
Triamcinolone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000205	0.000982	CcSEcCtD
Triamcinolone—Shock—Doxorubicin—thyroid cancer	0.000205	0.000981	CcSEcCtD
Triamcinolone—Insomnia—Epirubicin—thyroid cancer	0.000204	0.000975	CcSEcCtD
Triamcinolone—Tachycardia—Doxorubicin—thyroid cancer	0.000203	0.000973	CcSEcCtD
Triamcinolone—Paraesthesia—Epirubicin—thyroid cancer	0.000202	0.000968	CcSEcCtD
Triamcinolone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000201	0.000964	CcSEcCtD
Triamcinolone—Dyspnoea—Epirubicin—thyroid cancer	0.000201	0.000961	CcSEcCtD
Triamcinolone—Dyspepsia—Epirubicin—thyroid cancer	0.000198	0.000948	CcSEcCtD
Triamcinolone—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000198	0.00541	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000194	0.00533	CbGpPWpGaD
Triamcinolone—Fatigue—Epirubicin—thyroid cancer	0.000194	0.000929	CcSEcCtD
Triamcinolone—Pain—Epirubicin—thyroid cancer	0.000193	0.000921	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00019	0.000908	CcSEcCtD
Triamcinolone—NR3C1—Generic Transcription Pathway—THRB—thyroid cancer	0.000189	0.00519	CbGpPWpGaD
Triamcinolone—Insomnia—Doxorubicin—thyroid cancer	0.000188	0.000902	CcSEcCtD
Triamcinolone—Paraesthesia—Doxorubicin—thyroid cancer	0.000187	0.000895	CcSEcCtD
Triamcinolone—Dyspnoea—Doxorubicin—thyroid cancer	0.000186	0.000889	CcSEcCtD
Triamcinolone—Feeling abnormal—Epirubicin—thyroid cancer	0.000186	0.000888	CcSEcCtD
Triamcinolone—Dyspepsia—Doxorubicin—thyroid cancer	0.000183	0.000878	CcSEcCtD
Triamcinolone—Fatigue—Doxorubicin—thyroid cancer	0.00018	0.00086	CcSEcCtD
Triamcinolone—Urticaria—Epirubicin—thyroid cancer	0.000179	0.000856	CcSEcCtD
Triamcinolone—Pain—Doxorubicin—thyroid cancer	0.000178	0.000853	CcSEcCtD
Triamcinolone—Body temperature increased—Epirubicin—thyroid cancer	0.000178	0.000852	CcSEcCtD
Triamcinolone—Feeling abnormal—Doxorubicin—thyroid cancer	0.000172	0.000822	CcSEcCtD
Triamcinolone—Hypersensitivity—Epirubicin—thyroid cancer	0.000166	0.000794	CcSEcCtD
Triamcinolone—Urticaria—Doxorubicin—thyroid cancer	0.000166	0.000792	CcSEcCtD
Triamcinolone—Body temperature increased—Doxorubicin—thyroid cancer	0.000165	0.000788	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—HIF1A—thyroid cancer	0.000164	0.00449	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000162	0.00445	CbGpPWpGaD
Triamcinolone—Asthenia—Epirubicin—thyroid cancer	0.000162	0.000773	CcSEcCtD
Triamcinolone—Pruritus—Epirubicin—thyroid cancer	0.000159	0.000762	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000157	0.00429	CbGpPWpGaD
Triamcinolone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000154	0.000735	CcSEcCtD
Triamcinolone—Asthenia—Doxorubicin—thyroid cancer	0.00015	0.000715	CcSEcCtD
Triamcinolone—Dizziness—Epirubicin—thyroid cancer	0.000149	0.000713	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000148	0.00406	CbGpPWpGaD
Triamcinolone—Pruritus—Doxorubicin—thyroid cancer	0.000147	0.000705	CcSEcCtD
Triamcinolone—Vomiting—Epirubicin—thyroid cancer	0.000143	0.000685	CcSEcCtD
Triamcinolone—BCHE—Metabolism—MINPP1—thyroid cancer	0.000143	0.00391	CbGpPWpGaD
Triamcinolone—Rash—Epirubicin—thyroid cancer	0.000142	0.000679	CcSEcCtD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000142	0.00389	CbGpPWpGaD
Triamcinolone—Dermatitis—Epirubicin—thyroid cancer	0.000142	0.000679	CcSEcCtD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000141	0.00388	CbGpPWpGaD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000141	0.00387	CbGpPWpGaD
Triamcinolone—Headache—Epirubicin—thyroid cancer	0.000141	0.000675	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—PPARG—thyroid cancer	0.000139	0.00381	CbGpPWpGaD
Triamcinolone—Dizziness—Doxorubicin—thyroid cancer	0.000138	0.000659	CcSEcCtD
Triamcinolone—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000135	0.00371	CbGpPWpGaD
Triamcinolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000135	0.00369	CbGpPWpGaD
Triamcinolone—Nausea—Epirubicin—thyroid cancer	0.000134	0.00064	CcSEcCtD
Triamcinolone—Vomiting—Doxorubicin—thyroid cancer	0.000132	0.000634	CcSEcCtD
Triamcinolone—Rash—Doxorubicin—thyroid cancer	0.000131	0.000629	CcSEcCtD
Triamcinolone—Dermatitis—Doxorubicin—thyroid cancer	0.000131	0.000628	CcSEcCtD
Triamcinolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000131	0.00359	CbGpPWpGaD
Triamcinolone—Headache—Doxorubicin—thyroid cancer	0.000131	0.000625	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000128	0.0035	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—TRIM33—thyroid cancer	0.000126	0.00346	CbGpPWpGaD
Triamcinolone—Nausea—Doxorubicin—thyroid cancer	0.000124	0.000592	CcSEcCtD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000123	0.00337	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NDUFA13—thyroid cancer	0.000121	0.00332	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—MEN1—thyroid cancer	0.00012	0.0033	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CHST14—thyroid cancer	0.000114	0.00312	CbGpPWpGaD
Triamcinolone—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00011	0.00301	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000108	0.00297	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—TP53—thyroid cancer	0.000107	0.00293	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000106	0.00291	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000106	0.0029	CbGpPWpGaD
Triamcinolone—BCHE—Phospholipid metabolism—PTEN—thyroid cancer	0.0001	0.00275	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TRIM24—thyroid cancer	9.96e-05	0.00273	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—MINPP1—thyroid cancer	9.81e-05	0.00269	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—thyroid cancer	9.42e-05	0.00258	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CHST14—thyroid cancer	9.36e-05	0.00257	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—HPGD—thyroid cancer	9.18e-05	0.00252	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	9.16e-05	0.00251	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—THRB—thyroid cancer	9.12e-05	0.0025	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TRIM33—thyroid cancer	8.88e-05	0.00243	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NDUFA13—thyroid cancer	8.34e-05	0.00229	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—BRAF—thyroid cancer	8.1e-05	0.00222	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	8.1e-05	0.00222	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—RXRA—thyroid cancer	8.05e-05	0.00221	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	8.03e-05	0.0022	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—thyroid cancer	7.96e-05	0.00218	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	7.88e-05	0.00216	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CHST14—thyroid cancer	7.84e-05	0.00215	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.45e-05	0.00204	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	6.7e-05	0.00184	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—HPGD—thyroid cancer	6.32e-05	0.00173	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—TPR—thyroid cancer	6.16e-05	0.00169	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TCF7L1—thyroid cancer	5.92e-05	0.00162	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.83e-05	0.0016	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—MEN1—thyroid cancer	5.79e-05	0.00159	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	5.51e-05	0.00151	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	5.34e-05	0.00146	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	5.32e-05	0.00146	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TPR—thyroid cancer	5.28e-05	0.00145	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PRKAR1A—thyroid cancer	5.19e-05	0.00142	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.13e-05	0.00141	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—PPARG—thyroid cancer	5.08e-05	0.00139	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	4.86e-05	0.00133	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.7e-05	0.00129	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TPR—thyroid cancer	4.34e-05	0.00119	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.28e-05	0.00117	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PRKAR1A—thyroid cancer	4.27e-05	0.00117	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	4.08e-05	0.00112	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MEN1—thyroid cancer	4.08e-05	0.00112	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SLC5A5—thyroid cancer	3.95e-05	0.00108	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—RXRA—thyroid cancer	3.88e-05	0.00106	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—HRAS—thyroid cancer	3.72e-05	0.00102	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.7e-05	0.00101	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.64e-05	0.000998	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TPR—thyroid cancer	3.63e-05	0.000995	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.63e-05	0.000995	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PRKAR1A—thyroid cancer	3.57e-05	0.000979	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CHST14—thyroid cancer	3.43e-05	0.000939	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—RXRA—thyroid cancer	3.32e-05	0.000909	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CALCA—thyroid cancer	3.25e-05	0.00089	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.24e-05	0.000887	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.23e-05	0.000884	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.07e-05	0.00084	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CDK1—thyroid cancer	2.94e-05	0.000805	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—HPGD—thyroid cancer	2.76e-05	0.000757	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.72e-05	0.000745	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PPARG—thyroid cancer	2.45e-05	0.000671	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NRG1—thyroid cancer	2.36e-05	0.000646	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—RXRA—thyroid cancer	2.28e-05	0.000626	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.22e-05	0.000609	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TERT—thyroid cancer	2.12e-05	0.00058	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PPARG—thyroid cancer	2.09e-05	0.000574	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HIF1A—thyroid cancer	2.02e-05	0.000555	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—BRAF—thyroid cancer	1.68e-05	0.00046	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTGS2—thyroid cancer	1.65e-05	0.000452	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TPR—thyroid cancer	1.59e-05	0.000435	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.56e-05	0.000428	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PPARG—thyroid cancer	1.44e-05	0.000395	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTEN—thyroid cancer	1.44e-05	0.000394	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.19e-05	0.000325	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PTEN—thyroid cancer	1.18e-05	0.000324	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NRAS—thyroid cancer	1.05e-05	0.000289	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—RXRA—thyroid cancer	9.97e-06	0.000273	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PTEN—thyroid cancer	9.89e-06	0.000271	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—AKT1—thyroid cancer	9.67e-06	0.000265	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—KRAS—thyroid cancer	9.07e-06	0.000249	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—AKT1—thyroid cancer	8.28e-06	0.000227	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HRAS—thyroid cancer	7.71e-06	0.000211	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—AKT1—thyroid cancer	6.81e-06	0.000187	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PPARG—thyroid cancer	6.3e-06	0.000173	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—AKT1—thyroid cancer	5.7e-06	0.000156	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.95e-06	0.000136	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTEN—thyroid cancer	4.32e-06	0.000118	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—AKT1—thyroid cancer	2.49e-06	6.82e-05	CbGpPWpGaD
